ISSN 1866-8836
Клеточная терапия и трансплантация

Prognostic value of chimerism in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT)

Maria V. Pryanishnikova, Alexandra A. Sipol, Irina S. Solomonova, Ildar M. Barkhatov, Elena V. Semenova, Liudmila S. Zubarovskaya, Boris V. Afanasyev

Memorial R.M. Gorbacheva Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, St. Petersburg, Russia

Correspondence
Alexandra A. Sipol, Laboratory of Molecular Hematology, Memorial R.M. Gorbacheva Institute of Children Hematology and Transplantation, St. Petersburg Pavlov State Medical University, 6/8, Tolstoy str., St. Petersburg, 199044, Russia
Phone: +7 (911) 909-6548, fax: (812) 234-0616, E-mail: sipol_sanjka@mail.ru
doi 10.3205/ctt-2009-No5-abstract54

Download PDF version

Cellular Therapy and Transplantation (CTT)
Volume 2, Number 1(5)
Contents 

Summary

Introduction

For the last 20 years allo–HSCT has been one of the most effective treatments for different hematological malignancies. Hematopoietic chimerism analysis is an important method of monitoring the post-allo-HSCT outcome.

Patients and methods

In the study we included 142 patients with different hematological malignancies allografted between October 2002 and October 2008. The chimerism status was assessed by analyzing short tandem repeat polymorphisms.

Results

Overall survival in patients with complete donor chimerism on day +28 after allo-HSCT was 55% and 17% in patients with mixed chimerism or an absence of chimerism on the same day (p=0.0124). Similar results were observed by analyzing chimerism on day +60 following allo-HSCT. There were no significant differences in overall survival depending on chimerism value on day +28 and +60 in patients with myeloablative and nonmyeloablative conditioning regimen.

Of the patients with mixed chimerism or an absence of chimerism on day +28 after allo-HSCT, 67% had disease relapse, while 33% remained in remission (p=0.023).

Conclusions

Complete donor chimerism on day +28 and day +60 after allo-HSCT is associated with better prognosis. Mixed chimerism at day +28 after allo-HSCT is associated with an increased risk of relapse.

Keywords

chimerism, allo-HSCT, relapse, outcome


Back to the list